Related Experiment Video

Updated: Apr 18, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.9K

Cardiac rehabilitation and risk reduction: time to "rebrand and reinvigorate"

Pratik B Sandesara1, Cameron T Lambert1, Neil F Gordon2

  • 1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

Journal of the American College of Cardiology
|January 31, 2015
PubMed

Insights

Atherosclerotic cardiovascular disease (ASCVD) is rising, yet cardiac rehabilitation (CR) is underused. Improving CR delivery is crucial for effective secondary ASCVD prevention.

Area of Science:

  • Cardiology
  • Public Health
  • Preventive Medicine

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) incidence and costs are increasing annually in the US.
  • Multidisciplinary cardiac rehabilitation (CR) and risk reduction programs are vital for ASCVD prevention and management.
  • Despite strong evidence, CR is significantly underutilized due to various barriers.

Purpose of the Study:

  • To highlight the underutilization of cardiac rehabilitation (CR) in atherosclerotic cardiovascular disease (ASCVD) secondary prevention.
  • To emphasize the need for improvements in the current CR delivery model.
  • To advocate for a more sustainable, cost-effective, and patient-centered approach to secondary ASCVD prevention.

Main Methods:

  • Review of current literature on ASCVD trends and CR utilization.
  • Analysis of barriers to CR program access and adherence.
  • Discussion of the limitations of the existing CR delivery model.

Main Results:

  • ASCVD continues its upward trend in the United States, imposing substantial economic burdens.
  • Cardiac rehabilitation (CR) remains a vastly underutilized but evidence-based strategy for secondary ASCVD prevention.
  • Significant barriers impede widespread access to and participation in CR programs.

Conclusions:

  • The current model for delivering cardiac rehabilitation (CR) is unsustainable for comprehensive secondary ASCVD prevention.
  • Improvements are necessary to enhance the cost-effectiveness and patient-centeredness of CR.
  • Addressing barriers to CR is essential to increase its utilization and improve ASCVD outcomes.

Keywords:
exerciseheart diseasesecondary prevention

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
435
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.4K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801